Last updated on February 2018

Evaluation of Medical Practice in the Management of Bone Metastases After Injectable Bone Antiresorptive Treatment and Its Influence on Quality of Life

Brief description of study

To evaluate the current medical practice and its influence on health-related quality of life, in patients who are treated with injectable bone antiresorptive drugs (biphosphonates or denosumab) for at least one year.

Detailed Study Description

This protocol will evaluate the pursuit of injectable bone antiresorptive treatments or their switch to oral biphosphonates, or treatment stop, in the contexte of medical practice.

The primary end-point is the health-related quality of life (QoL). Secondary endpoints are safety, overall survial, the impact of toxicities of the treatment on QoL, and the description of supportive care.

Clinical Study Identifier: NCT02839291

Find a site near you

Start Over